ALK-negative Anaplastic Large Cell Lymphoma (DBCOND0060684)

Identifiers

Synonyms

Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / ALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (morphologic abnormality) / Anaplastic lymphoma kinase negative anaplastic large cell lymphoma (disorder)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06176690	Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas	No drug interventions	treatment	1	not_yet_recruiting
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Tislelizumab	treatment	2	completed
NCT01035463	Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Lenalidomide Mechlorethamine Rituximab	treatment	1 / 2	completed
NCT04480788	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study	No drug interventions	treatment	1	unknown_status
NCT03113500	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma	Beta-D-Glucose Brentuximab vedotin Cortisone Cyclophosphamide Daunorubicin Doxorubicin Etoposide Prednisone	treatment	2	active_not_recruiting
NCT03040206	Risk Stratification of Nodal PTCL	No drug interventions	Not Available	Not Available	completed
NCT05978141	A Registry for People With T-cell Lymphoma	No drug interventions	Not Available	Not Available	recruiting
NCT01719835	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study	Cisplatin Cyclophosphamide Doxorubicin Gemcitabine Methylprednisolone Prednisolone Vincristine	treatment	2	unknown_status
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Nivolumab Talimogene laherparepvec	treatment	2	active_not_recruiting
NCT01198665	RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas	Cyclophosphamide Doxorubicin Everolimus Prednisolone Vincristine	treatment	1 / 2	completed
NCT02561273	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Beta-D-Glucose Cortisone Cyclophosphamide Doxorubicin Etoposide Lenalidomide Prednisone Sulfate ion Vincristine	treatment	1 / 2	completed
NCT02533700	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL	No drug interventions	treatment	2	unknown_status
NCT01746992	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma	Cyclophosphamide Doxorubicin Etoposide Ifosfamide Methotrexate Pirarubicin Prednisone Vincristine	treatment	4	unknown_status
NCT00901147	Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma	Bortezomib Bortezomib D-mannitol Panobinostat	treatment	2	completed
NCT02223208	Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas	Cyclophosphamide Doxorubicin Etoposide Prednisone Romidepsin Vincristine	treatment	1 / 2	active_not_recruiting